EMEA-002124-PIP01-17
Key facts
| Active substance |
Pexastimogene devacirepvec
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0201/2017
|
| PIP number |
EMEA-002124-PIP01-17
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Treatment of hepatocellular carcinoma
|
| Route(s) of administration |
Intratumoral use
|
| Contact for public enquiries |
Transgene S.A.
|
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|